Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18541684 | 0.83 | — | — | |
| SCHEMBL10948280 | 0.82 | TSHR (0.44) | SMN1; SMN2TSHRALDH1A1LMNAPOLB | |
| SCHEMBL8515087 | 0.79 | SMN1; SMN2 (0.42) | PDK1SMN1; SMN2TSHRALDH1A1TDP1 | |
| SCHEMBL6303714 | 0.79 | — | — | |
| SCHEMBL19404112 | 0.79 | — | — | |
| SCHEMBL25594497 | 0.78 | SMN1; SMN2 (0.32) | PDK1SMN1; SMN2TSHRALDH1A1TDP1 | |
| SCHEMBL15683100 | 0.77 | SMN1; SMN2 (0.31) | PDK1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL31680332 | 0.77 | SMN1; SMN2 (0.31) | PDK1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL12527246 | 0.77 | SMN1; SMN2 (0.31) | PDK1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL16809957 | 0.76 | ALDH1A1 (0.50) | PDK1SMN1; SMN2TSHRALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976381-B1 | TRI-SUBSTITUTED 2-BENZHYDRYL-5-BENZLAMINO-TETRAHYDRO-PYRAN-4-OL AND 6-BENZHYDRYL-4-BENZYLAMINO-TETRAHYDRO-PYRAN-3-OL ANALOGUES, AND NOVEL 3,6-DISUBSTITUTED PYRAN DERIVATIVES | UNIV WAYNE STATE (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | GENENTECH, INC. | 2012-06-21 | — | — | US | disclosed |
| WO-2012071458-A1 | HETEROCYCLIC INHIBITORS OF BETA - SECRETASE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | PDK1 761/4885SMN1; SMN2 54/4885TSHR 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.